Core Insights - Scilex Holding Company has successfully closed the second tranche of its strategic investment in Datavault AI, acquiring shares valued at approximately $583.3 million based on the closing price of Datavault's common stock [1][5]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for treating acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [3][4]. - The company has several commercial products, including ZTlido® for neuropathic pain, ELYXYB® for acute migraine treatment, and Gloperba® for gout flare prophylaxis [3][4]. Product Development - Scilex has three product candidates in development: - SP-102, a viscous gel for lumbosacral radicular pain, which has completed Phase 3 studies and received Fast Track status from the FDA [4]. - SP-103, a next-generation lidocaine topical system for acute pain, which has recently completed a Phase 2 trial [4]. - SP-104, a low-dose naltrexone for fibromyalgia treatment, is also under development [6]. Strategic Investment - The strategic investment in Datavault AI involves the purchase of a pre-funded warrant for 263,914,094 shares of Datavault AI common stock, with the transaction being approved by Datavault's stockholders [5]. - Both companies plan to enhance collaboration to drive growth in Real World Asset tokenization starting in 2026 [5]. Datavault AI Overview - Datavault AI specializes in AI-driven data experiences and asset monetization, offering solutions across various industries, including biotech, fintech, and healthcare [7]. - The company’s platform includes technologies for audio transmission and high-performance computing, enabling secure monetization and data analytics [7].

Core Insights - Datavault AI has successfully closed the second tranche of equity financing with Scilex Holding Company, issuing a pre-funded warrant for approximately 263.91 million shares in exchange for about 1,237.6 Bitcoin [1][8] - The strategic investment aims to provide growth capital to enhance Datavault's digital asset reserves, accelerate supercomputing infrastructure, and support platform expansion [2] - Datavault has granted Scilex an exclusive worldwide license for its AI-driven technology tailored for the biotech and biopharma industry, which includes a nonrefundable upfront license fee totaling $10 million and potential sales milestone payments of up to $2.55 billion [3][4] Financial Details - The initial tranche of Scilex's investment was closed on September 26, 2025, valued at approximately $8 million in Bitcoin [1][8] - The second tranche involves a purchase of approximately 1,237.6 Bitcoin, reflecting a significant investment in Datavault's future growth [1][8] - Scilex will pay the upfront license fee in four equal installments of $2.5 million, with the first payment due by December 31, 2025 [4] Leadership Commentary - Scilex CEO Henry Ji expressed confidence in the collaboration, highlighting the alignment of Datavault's technologies with the biotech sector's needs for advanced data analytics and supercomputing power [5] - Datavault AI CEO Nathanial Bradley welcomed Scilex as a major stockholder, emphasizing the shared vision for leveraging digital assets to capture market share in the biotech sector [5] Company Overview - Datavault AI specializes in AI-driven data experiences and asset monetization in the Web 3.0 environment, offering solutions across various industries including biotech, fintech, and healthcare [6][7] - The company's technology suite includes patented technologies for audio transmission and high-performance computing solutions [6][7]

Core Viewpoint - Scilex Holding Company announced the distribution of a Dream Bowl 2026 Meme Coin to eligible stockholders in collaboration with Datavault AI, with a record date set for November 25, 2025, and an ex-dividend date of November 24, 2025 [1][2]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [6][8]. - The company has commercial products including ZTlido® for neuropathic pain, ELYXYB® for acute migraine treatment, and Gloperba® for gout flare prophylaxis [7][8]. Product Candidates - Scilex has three product candidates: - SP-102, a viscous gel for treating lumbosacral radicular pain, which has completed Phase 3 studies and received Fast Track status from the FDA [8]. - SP-103, a next-generation lidocaine topical system for acute pain, which has completed Phase 2 trials and also received Fast Track status [8]. - SP-104, a low-dose naltrexone hydrochloride for fibromyalgia treatment [8]. Datavault AI Overview - Datavault AI is focused on AI-driven data experiences and monetization of assets, providing solutions across various industries including sports, entertainment, and healthcare [10][11]. - The company’s technology suite includes patented technologies for audio transmission and high-performance computing solutions for data perception and monetization [10]. Event Details - The Dream Bowl event will take place on January 11, 2026, at AT&T Stadium in Dallas, Texas, featuring elite athletes and e-sports competitions [4].

Core Insights - Scilex Holding Company is sponsoring the Dream Bowl 2026 and will distribute a unique digital collectible, the Dream Bowl 2026 Meme Coin, to its shareholders [1][2] - Shareholders as of November 14, 2025, will receive one meme coin for each common share held, with airdrops occurring on or after November 25, 2025 [2] - The Dream Bowl event will take place on January 11, 2026, at AT&T Stadium in Dallas, Texas, featuring elite athletes and e-sports competitions [3] Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [1][4] - The company has commercial products including ZTlido® for neuropathic pain, ELYXYB® for acute migraine treatment, and Gloperba® for gout flare prophylaxis [4][5] - Scilex is developing three product candidates: SP-102 for lumbosacral radicular pain, SP-103 for acute pain, and SP-104 for fibromyalgia [5][6] Datavault AI Partnership - Datavault AI is involved in the distribution of the meme coin and offers a cloud-based platform for data experiences and monetization [7] - The partnership aims to enhance the recognition of ownership and provide utility through ticketing and event insights for the Dream Bowl [2][3]

Core Viewpoint - Scilex Holding Company has completed the initial tranche of a $150 million investment in Datavault AI Inc., acquiring 15 million shares at an effective price of $0.5378 per share, with potential for additional shares pending stockholder approval [1]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [3][5]. - The company targets high unmet needs in the market with its non-opioid therapies, aiming to improve patient outcomes [3]. Commercial Products - Scilex's commercial products include: - ZTlido® (lidocaine topical system) 1.8%, approved for neuropathic pain relief [3]. - ELYXYB®, an FDA-approved oral solution for acute migraine treatment [3]. - Gloperba®, the first liquid oral version of colchicine for gout flare prophylaxis [3]. Product Candidates - Scilex has three product candidates in development: - SP-102 (SEMDEXA), a viscous gel for epidural injections to treat sciatica, which has completed Phase 3 studies and received Fast Track status from the FDA [4]. - SP-103, a next-generation lidocaine topical system for acute pain, recently completed a Phase 2 trial and has also received Fast Track status [4]. - SP-104, a low-dose naltrexone hydrochloride for fibromyalgia treatment [4]. Investment Details - The initial tranche of the investment in Datavault AI Inc. involves the acquisition of 15 million shares, with the potential for up to 278,914,094 shares in total, subject to stockholder approval [1]. - The effective purchase price for the shares is $0.5378, with adjustments possible for stock splits [1].

Core Viewpoint - Scilex Holding Company has announced a strategic investment of $150 million in Bitcoin in Datavault AI Inc. to support its growth in supercomputing infrastructure and data monetization [1][3]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [6][7]. - Datavault AI is positioned to leverage AI-driven analytics and blockchain technology to address challenges in data integrity and monetization across various industries, including biotech and energy [2][11]. Investment Details - The investment will provide Datavault with growth capital to expand its operations and unlock new revenue streams [1]. - Scilex is expected to receive up to 278,914,094 shares of Datavault common stock at an effective purchase price of $0.5378 per share, with specific terms regarding share issuance and board representation [4]. Market Potential - The global AI market is projected to reach $1.8 trillion by 2030, while the life sciences analytics market is estimated at $35.69 billion in 2024, growing at an 11.4% CAGR through 2030 [2]. - The biotech data monetization market is expected to reach a size of $30-50 billion by 2024, indicating significant growth potential for Scilex's investment strategy [3]. Strategic Alignment - Scilex aims to leverage its expertise in the biotech sector to guide Datavault in maximizing revenue generation while expanding its market presence [5]. - The collaboration is expected to create a marketplace for Real-World Assets (RWA) in the biotech and pharmaceutical industry, utilizing blockchain technology for ownership representation [3].

Core Viewpoint - Scilex Holding Company has signed a non-binding Memorandum of Understanding (MOU) with Biconomy.com to explore future cryptocurrency and treasury management strategies, potentially involving over a billion dollars in digital assets [1][2]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [4][6]. - The company targets high unmet needs and large market opportunities with non-opioid therapies, aiming to improve patient outcomes [4]. Product Portfolio - Scilex's commercial products include: - ZTlido® (lidocaine topical system) 1.8%, approved for neuropathic pain relief [4]. - ELYXYB®, an FDA-approved oral solution for acute migraine treatment [4]. - Gloperba®, the first liquid oral version of colchicine for gout flare prophylaxis [4]. - The company has three product candidates in development: - SP-102 (SEMDEXA), a viscous gel for lumbosacral radicular pain, with a completed Phase 3 study and Fast Track status from the FDA [5]. - SP-103, a next-generation lidocaine topical system for acute pain, recently completing a Phase 2 trial [5]. - SP-104, a low-dose naltrexone hydrochloride for fibromyalgia treatment [5]. Strategic Collaboration - The MOU with Biconomy aims to establish a cryptocurrency treasury management strategy that balances security, liquidity, compliance, and yield [2]. - The collaboration is intended to create long-term value in Scilex's digital assets and support the transition to a crypto-powered economy [3].

Core Viewpoint - Scilex Holding Company announced the successful closing of a business combination with Denali Capital Acquisition Corp, resulting in the formation of Semnur Pharmaceuticals, Inc., which will focus on non-opioid pain management products [1][2][3] Company Overview - Scilex is dedicated to acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [1][5] - The company aims to address high unmet needs in the market with its innovative therapies [5] Business Combination Details - The combined entity will operate under the name Semnur Pharmaceuticals, Inc., with shares trading on the OTC Markets under the ticker symbols "SMNR" and "SMNRW" [2][6] - Scilex holds approximately 87.5% of Semnur's common stock post-business combination [6] Leadership Statements - Henry Ji, CEO of Scilex, emphasized the importance of public capital markets for business growth and fulfilling the mission of addressing non-opioid pain management needs [3] - Jaisim Shah, CEO of Semnur, expressed pride in leading the development of prescription non-opioid therapeutics and aims to accelerate access to these treatments [3] Product Pipeline - Semnur's lead product candidate, SP-102 (SEMDEXA), is a novel gel formulation for epidural administration targeting chronic radicular pain/sciatica [10] - Scilex has additional product candidates, including SP-103 and SP-104, targeting acute pain and fibromyalgia, respectively [8]

Core Viewpoint - Scilex Holding Company has regained compliance with Nasdaq's minimum closing bid price requirement, maintaining a minimum closing bid price of $1.00 per share for at least ten consecutive trading days as of April 30, 2025 [1] Company Overview - Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [3][5] - The company targets high unmet needs and large market opportunities with non-opioid therapies to improve patient outcomes [3] Commercial Products - Scilex's commercial products include: - ZTlido® (lidocaine topical system) 1.8%, approved for neuropathic pain relief associated with postherpetic neuralgia [3] - ELYXYB®, the only FDA-approved ready-to-use oral solution for acute migraine treatment in adults [3] - Gloperba®, the first liquid oral version of colchicine for the prophylaxis of painful gout flares in adults [3] Product Candidates - Scilex has three product candidates in development: - SP-102 (SEMDEXA), a viscous gel formulation for epidural injections to treat lumbosacral radicular pain, which has completed a Phase 3 study and received Fast Track status from the FDA [4] - SP-103, a next-generation formulation of ZTlido for acute pain, which has recently completed a Phase 2 trial and also received Fast Track status from the FDA [4] - SP-104, a low-dose delayed-release naltrexone hydrochloride for fibromyalgia treatment [4]